Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab in Asymptomatic Active Brain Metastases From Small Cell Lung Cancer
NCT07402343Phase 2Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Aug 2026
- Primary completion
- Feb 2029
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 2 trial of tarlatamab in small cell lung cancer (SCLC), brain metastases, sponsored by Maastricht University Medical Center+. Started Aug 2026; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)brain metastases
Beyond the preview
Go deeper on NCT07402343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07402343.